Covidien (NYSE: COV) introduces its proprietary Tri-Staple™ technology platform for endoscopic stapling. The technology enables surgeons to use staplers in a wider variety of laparoscopic procedures and in a broader range of tissue thicknesses than ever before.
The new Endo GIA stapling system includes an ergonomically enhanced, lightweight handle designed for precise control. The easy-to-use stapling solution features unique reloads using Tri-Staple technology to deliver outstanding performance across a wider range of tissue thicknesses. The end result is simplified cartridge selection, a new grasping feature for improved tissue maneuverability, advanced compression for increased tissue stability and significantly less force needed for firing.
Clinical field tests support the use of the new Endo GIA Reloads with Tri-Staple technology and the new Endo GIA Ultra Universal stapler in thoracic, bariatric, colorectal, general, hepatobiliary, urological and gynecological surgery. In addition, as part of its commitment to evidence-based medicine, Covidien is sponsoring clinical trials using the new stapling system, including bariatric and thoracic studies. Covidien plans to present interim and final results from these clinical studies at key conferences throughout the year.
For more information, visit www.covidien.com